A dozen Indian generic semaglutide brands launch on day one

At least six Indian drugmakers launched generic semaglutide on March 21, 2026, one day after Novo Nordisk's core Indian patent on the molecule expired. ^[1][2][3] Semaglutide is the active ingredient in Ozempic and Wegovy. The launches undercut Novo's Indian prices by roughly 50% to 80%, according to company announcements and analysts. ^[3]

Dr. Reddy's Laboratories, which says it was the first Indian company to win approval from the Drugs Controller General of India (DCGI) for generic semaglutide, launched a pre-filled disposable pen called Obeda at about 4,200 rupees per month for the 2 mg and 4 mg doses, currently cleared for type 2 diabetes. ^[1][2] The company said it is separately seeking approval for weight management. ^[2] In a head-to-head Phase 3 trial of 312 participants, Dr. Reddy's said Obeda showed non-inferior efficacy and a comparable safety profile to the originator, with similar blood sugar reductions and no anti-drug antibodies detected. ^[2]

Other day-one entrants spanned a wide price range. Glenmark's GLIPIQ, sold in vials that require a syringe, runs 325 to 440 rupees per week, or 1,300 to 1,760 rupees per month — the cheapest option reported. ^[1][2] Alkem launched Semasize, Obesema and Hepaglide in a pre-filled pen starting at 1,800 rupees a month, about 450 rupees a week, with a reusable pen for higher maintenance doses. ^[1][2] Zydus launched Semaglyn, Mashema and Alterme in a reusable multi-dose pen at an average of roughly 2,200 rupees a month, with co-marketing deals signed with Lupin and Torrent. ^[1][2] Sun Pharma launched Noveltreat for weight management (900 to 2,000 rupees a week, or 3,600 to 8,000 a month) and Sematrinity for type 2 diabetes (750 to 1,300 rupees a week). ^[1][2] Natco Pharma began selling Semanat and Semafull in vial form from 1,290 rupees a month, with a pen device expected in April at 4,000 to 4,500 rupees; Eris Lifesciences priced its partner brand Sundae at the same starting rate. ^[2] Sources differ slightly on Natco's vial price, with CNBC reporting 1,250 rupees a month. ^[3]

By comparison, Novo's branded semaglutide retails in India for about 8,800 to 10,000 rupees a month depending on dose, per CNBC; ThePrint puts Ozempic and Wegovy starting doses at 8,800 and 10,850 rupees. ^[2][3] Novo cut Wegovy's Indian price by 37% from its launch price in December, before the patent lapsed. ^[3] Novo Nordisk India managing director Vikrant Shrotriya said, "Our size, technology, and complete care ecosystem justify the price we are getting after a 37% reduction." ^[3] The company is also launching second brands: Wegovy as Poviztra with Emcure Pharma and Ozempic as Extensior with Abbott India. ^[3]

Why it matters for patients

For US patients, the direct effect is none — for now. Semaglutide remains protected from generic competition in the United States until 2032, its largest market by far. ^[3] Patents expired or are expiring this year in India, Canada, Brazil and China. ^[3] Dr. Reddy's says it plans to expand to Canada, Turkey and Brazil this year and is targeting 12 million pens in its first year across all markets. ^[3]

The Indian launches are a preview of what price competition can look like once exclusivity ends, and they may pressure Novo's global revenue. The company warned in February that sales could fall 5% to 13% in 2026. ^[3]

There is also a caution embedded in the story. Peptide drugs like semaglutide need specialized manufacturing and cold-chain storage. "The molecule that is given to patients has to be perfect, and it cannot have any side products or contaminants," said Knud Jensen, a chemistry professor at the University of Copenhagen and president of the European Peptide Society. ^[3] Some industry watchers told CNBC they worry Indian-made generic semaglutide could leak into markets where the drug is still patented — meaning product sold outside legal channels in the US would not be an approved generic. ^[3] Mumbai diabetologist Rajiv Kovil said he plans to wait for more evidence on effectiveness and availability before switching patients. ^[3]

What happens next

More than 50 semaglutide brands are expected to launch in India in the coming months. ^[3] Natco's pen device is due in April. ^[2] Whether Novo holds its lead is unsettled: Sydbank analyst Søren Løntoft Hansen said it is not yet clear, while Systematix analyst Vishal Manchanda said Novo could keep a large share if it holds a 15% to 20% premium. ^[3]